Product Theater hosted by Medimaps Group
As a validated index of bone microarchitecture, trabecular bone score (TBS), alongside bone mineral density and clinical risk factors, enhances the assessment and management of osteoporosis. The large body of evidence, comprising more than 1,200 peer-reviewed studies, and the adoption by healthcare facilities in over 60 countries, underpins this approach as a recognized standard of care. Not only does it refine the accuracy of fracture risk assessment, but it also has the potential to guide more personalized treatment strategies.
Join clinical experts in this virtual Product Theater Session to learn more. Participants will gain insights into the latest evidence and guidelines, understand the nuances of the Medicare reimbursement process, and explore the innovative future applications of TBS technology. The session will close with Q&A, offering an opportunity for attendees to engage directly with subject matter experts.
TBS: Guideline Updates, US Reimbursement, and Forthcoming Capabilities
Sunday, April 21, 1:00pm-2:00pm EDT
Meet the speakers
- Prof. Karen Hind, Ph.D., Honorary Fellow in the Wolfson Research Institute of Durham University, UK, and is Director of Clinical Affairs and Innovation at Medimaps Group
- Dr. Lauren Nicola, MD., Radiologist, Chief Executive Officer at Triad Radiology, NC
- Prof. Didier Hans, Ph.D., MBA., Head of Research and Development in the Bone and Joint Department at the Interdisciplinary Center of Bone Disease at Lausanne University Hospital, Switzerland and Co-founder and CEO at Medimaps Group
NOTE: This session is a sponsored presentation, and attendees will not receive ACCME credit.
The information in this session is provided by Medimaps Group and is not endorsed by ISCD.